Zoledronic acid combined with chemotherapy in non-small cell lung cancer with bone metastasis.

Purpose: We aimed to investigate the efficacy and safety of zoledronic acid combined with chemotherapy in treating non-small cell lung cancer (NSCLC) with bone metastasis.

Methods: The clinical data of 148 NSCLC patients with bone metastasis were retrospectively analyzed. Among the patients, 74 were treated with zoledronic acid combined with chemotherapy (Zoledronic Acid group), while the remaining 74 received chemotherapy alone (Control group).